The integrated stress response (ISR) is a conserved translational and transcriptional program affecting metabolism, memory, and immunity. The ISR is mediated by stress-induced phosphorylation of eukaryotic translation initiation factor 2a (eIF2a) that attenuates the guanine nucleotide exchange factor eIF2B. A chemical inhibitor of the ISR, ISRIB, reverses the attenuation of eIF2B by phosphorylated eIF2a, protecting mice from neurodegeneration and traumatic brain injury. We describe a 4.1-angstrom-resolution cryo-electron microscopy structure of human eIF2B with an ISRIB molecule bound at the interface between the b and d regulatory subunits. Mutagenesis of residues lining this pocket altered the hierarchical cellular response to ISRIB analogs in vivo and ISRIB binding in vitro. Our findings point to a site in eIF2B that can be exploited by ISRIB to regulate translation.
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T he integrated stress response (ISR) has homeostatic functions that increase fitness. However, in some pathological circumstances, benefit arises from attenuated signaling in the ISR (1) . A search for ISR inhibitors led to the discovery of the integrated stress response inhibitor, ISRIB (2), a small molecule efficacious in mouse models of neurodegeneration (3) and traumatic brain injury (4) .
ISRIB action converges on eukaryotic translation initiation factor 2B (eIF2B), a protein complex with guanine nucleotide exchange factor (GEF) activity toward eIF2 (5) that is inhibited by phosphorylated eIF2 (6, 7) . Addition of ISRIB accelerates eIF2B GEF activity in vitro, and targeting eIF2B's d regulatory subunit can impart ISRIB resistance (8, 9) . However, known ISRIBresistant mutations in eIF2B cluster at a distance from both the regulatory site engaged by eIF2(aP) and the catalytic site engaged by eIF2g (10) . Thus, although the bulk of the evidence suggests that ISRIB binds eIF2B to regulate its activity, indirect modes of action are not excluded.
ISRIB stabilized the eIF2B complex from HeLa cells ( fig. S1 ), as expected (9) . Thus, we added a fluorescently labeled derivative of ISRIB (AAA2-101) ( fig. S2A ) to purified eIF2B and observed increased fluorescence polarization (FP) (Fig. 1A, left panel) .
Unlabeled ISRIB competed for eIF2B in the FP assay with a half-maximal effective concentration (EC 50 ) in the nanomolar range (Fig. 1A , right panel). As observed for ISRIB action in cells, lessactive analogs competed less successfully ( fig. S2 , B and C).
We purified endogenous eIF2B from HeLa cell lysates in the presence of ISRIB and determined the structure of the complex by single-particle cryo-electron microscopy (cryo-EM) at an overall resolution of 4.1 Å (Fig. 1B, figs . S1A and S3, and table S6). Within the b and d regulatory core, protein side chains were clearly resolved, resulting in a near-complete atomic model of this region (Fig. 1C and fig. S4, A and B) . The resolution of the g and e human catalytic subcomplex was lower compared with that of the regulatory core ( fig. S4A) , and the catalytically important C-terminal HEAT domain of the e subunit remained unresolved in the cryo-EM map.
Owing to a lack of sufficient high-quality cryo-EM images of an apo-eIF2B complex, we were unable to calculate a difference map of eIF2B with and without ISRIB. However, a nearly continuous density with a shape and size of a single ISRIB molecule was conspicuously present at the interface of the b and d regulatory subunits (Fig. 1B,  "central view," and fig. S4C ). The ISRIB-binding 
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pocket was located at the plane of symmetry between the b and d subunits. In the central part of the pocket, the side chain of bH188 was positioned in the vicinity of the essential carbonyl moiety of ISRIB (11), and bN162 was poised to stabilize the diaminocyclohexane moiety of ISRIB through hydrogen-bonding interactions (Fig. 1D ). More distally, the side chains of dL179, dF452, dL485, dL487, bV164, bI190, bT215, and bM217 formed the hydrophobic end of the symmetrical pocket that accommodated the aryl groups of ISRIB, with bI190 and dL179 located within van der Waals interaction distance to the aryl group ( fig. S4D) . A hamster Eif2b4 L180F mutation (dL179 in the human eIF2B) disrupts ISRIB action in cells (8) , which is consistent with a potential loss of these interactions as well as a clash between the bulkier side chain of phenylalanine and the bound ISRIB molecule (Fig. 1D) .
Overall, the human structure is highly similar to that of the published Schizosaccharomyces pombe eIF2B structure (10) (root mean square deviation of 2.57 Å over 3049 a carbons, fig. S4E ).
However, there is no density in the corresponding region in the S. pombe eIF2B map, indicating that the density found in the human structure was that of the bound ISRIB.
To test these features of ISRIB binding, we used CRISPR-Cas9 to randomize residues lining the ISRIB-binding pocket (Eif2b2 Fig. 2A, left and right panels, respectively).
To determine if the phenotypically distinguished pools of mutagenized cells ( Fig. 2A) were enriched in different mutations, we subjected genomic DNA derived from each population to deepsequencing analysis (Fig. 2B and table S4 ). The ISRIB RES pool targeted at Eif 2b2 H188 diverged markedly from the parental sequence (Fig. 2B,  middle panel) . Of a total of 250,617 sequencing reads, histidine was present in only 6443 (2.6%), with arginine, glycine, leucine, lysine, and glutamine dominating (24, 21, 18, 8.2, and 6.2%, respectively). Histidine was preserved in the ISRIB SEN pool (269,253 of 328,113 reads, 82%). The ISRIB RES pool of cells targeted at Eif 2b2 I190 was dominated by tryptophan, methionine, and tyrosine (28, 24, and 15%, respectively), consistent with a role for these bulky side chains in occluding the ISRIBbinding pocket (Fig. 2B, bottom panel) . Mutagenesis of Eif 2b2 N162 was less successful in generating a pool of strongly ISRIB-resistant cells; nonetheless, threonine was enriched in the ISRIB RES pool (26%) (Fig. 2B, top panel) . Thus, residues lining the ISRIBbinding pocket play a role in ISRIB action.
Despite considerable allele diversity, the Eif 2b2 H188X ISRIB RES pool exhibited selective loss of sensitivity to ISRIB, while retaining a measure of responsiveness to certain ISRIB analogs . Shown is a representative from three independent experiments for each of the compounds. Concentration of inhibitor is represented on a log 10 scale. Curve fitting and EC 50 were generated using agonist versus response function on GraphPad Prism. (Fig. 2D) . The residual response to analogs AAA1-075B (075B) and AAA1-084 (084) (albeit with much reduced affinity compared to the ISRIB SEN population) (Fig. 2C ), pointed to a shift in the binding properties of the ISRIB pocket, induced by the mutations at b188.
Next, we exploited the diversity of ISRIB RES mutations in the Eif 2b2 H188X population to select for subpools that either acquired sensitivity to compounds AAA1-075B or AAA1-084, regained sensitivity to ISRIB, or retained ISRIB resistance (Fig. 3A) and sequenced their Eif 2b2 alleles (Fig. 3B  and table S5 ). As expected, sorting for ISRIB sensitivity enriched, by >20-fold, rare wild-type H188 alleles that persisted in the ISRIB
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H188X pool (Fig. 3B , compare purple and orange bars). H188 was also somewhat enriched in the pools of 075B SEN or 084 SEN cells, but unlike the ISRIB SEN , these pools were also enriched for residues other than histidine (Fig. 3B and table S5) . Notably, selecting for sensitivity to these ISRIB analogs enriched for different residues than those found in the original ISRIB RES pool: Arginine, glycine, and leucine were depleted and replaced by lysine, serine, alanine, and threonine (Fig.   3B , compare purple to blue and cyan bars). The correlation between mutations in residues lining the ISRIB-binding pocket and selective responsiveness to ISRIB analogs, observed in the pools, was confirmed in individual mutant clones ( fig. S5 ).
To directly address the effect of ISRIB-resistant mutations on ISRIB binding, we purified eIF2B from wild-type, Eif2b4
L180F
, and Eif2b2 H188K Chinese hamster ovary (CHO) cells (fig. S6 ). The wild-type eIF2B gave rise to a concentration-dependent FP signal in the presence of a fluorescein-labeled AAA2-101 that was readily competed with unlabeled ISRIB (Fig. 3C ). However, eIF2B purified from the mutant cells failed to give rise to an FP signal (Fig. 3D) , thereby establishing a correlation between ISRIB resistance in cells and defective ISRIB binding in vitro.
The ISRIB-binding pocket, defined structurally and validated chemogenetically, straddles the twofold axis of symmetry of the core regulatory subcomplex, and a single molecule of ISRIB appears to engage the same residues from opposing protomers of the (bd) 2 dimer. These features fit with ISRIB's own symmetry and could explain the ability of ISRIB to stabilize the eIF2B decamer, possibly increasing its abundance in ISRIB-treated cells. Our findings are also consistent with ISRIB's ability to stabilize a ratelimiting assembly intermediate of the active decamer, as demonstrated biochemically in an accompanying manuscript (12) . Indeed, comparison of the S. pombe (10) and ISRIB-bound human eIF2B argues against large domain movements associated with ISRIB binding. However, an important allosteric effect of ISRIB binding might easily have been overlooked, as the critical catalytic domain of the e subunit is resolved in neither structure. Similar considerations apply to the potential effect of ISRIB on the inhibitory interaction between eIF2B with eIF2(aP). These might arise from subtle ISRIB-induced conformational changes propagated through the regulatory core to the eIF2(aP) binding cavity formed by the convergence of the tips of the a, b, and d subunits (10, (13) (14) (15) . The lower resolution of the cryo-EM density in that region might have masked important allosteric changes. Although the relative contribution of accelerated assembly, enhanced stability, or allostery to ISRIB action remain to be resolved, it is intriguing to consider that endogenous ligands might engage the ISRIB-binding site to regulate eIF2B in yet-to-be-determined physiological states.
